Unknown

Dataset Information

0

Reversal of neurological deficits by painless nerve growth factor in a mouse model of Rett syndrome.


ABSTRACT: Rett syndrome is a rare genetic neurodevelopmental disease, affecting 1 in over 10 000 females born worldwide, caused by de novo mutations in the X-chromosome-located methyl-CpG-binding protein 2 (MeCP2) gene. Despite the great effort put forth by the scientific community, a therapy for this devastating disease is still needed. Here, we tested the therapeutic effects of a painless mutein of the nerve growth factor (NGF), called human NGF painless (hNGFp), via a non-invasive intranasal delivery in female MeCP2+/- mice. Of note, previous work had demonstrated a broad biodistribution of hNGFp in the mouse brain by the nasal delivery route. We report that (i) the long-term lifelong treatment of MeCP2+/- mice with hNGFp, starting at 2 months of age, increased the chance of survival while also greatly improving behavioural parameters. Furthermore, when we assessed the phenotypic changes brought forth by (ii) a short-term 1-month-long hNGFp-treatment, starting at 3 months of age (right after the initial presentation of symptoms), we observed the rescue of a well known neuronal target population of NGF, cholinergic neurons in the medial septum. Moreover, we reveal a deficit in microglial morphology in MeCP2+/- mice, completely reversed in treated animals. This effect on microglia is in line with reports showing microglia to be a TrkA-dependent non-neuronal target cell population of NGF in the brain. To understand the immunomodulatory activity of hNGFp, we analysed the cytokine profile after hNGFp treatment in MeCP2+/- mice, to discover that the treatment recovered the altered expression of key neuroimmune-communication molecules, such as fractalkine. The overall conclusion is that hNGFp delivered intranasally can ameliorate symptoms in the MeCP2+/- model of Rett syndrome, by exerting strong neuroprotection with a dual mechanism of action: directly on target neurons and indirectly via microglia.

SUBMITTER: Tiberi A 

PROVIDER: S-EPMC10766238 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Reversal of neurological deficits by painless nerve growth factor in a mouse model of Rett syndrome.

Tiberi Alexia A   Borgonovo Giulia G   Testa Giovanna G   Pacifico Paola P   Jacob Ajesh A   Di Caprio Mariachiara M   Totaro Valentino V   Calvello Mariantonietta M   Cattaneo Antonino A   Capsoni Simona S  

Brain : a journal of neurology 20240101 1


Rett syndrome is a rare genetic neurodevelopmental disease, affecting 1 in over 10 000 females born worldwide, caused by de novo mutations in the X-chromosome-located methyl-CpG-binding protein 2 (MeCP2) gene. Despite the great effort put forth by the scientific community, a therapy for this devastating disease is still needed. Here, we tested the therapeutic effects of a painless mutein of the nerve growth factor (NGF), called human NGF painless (hNGFp), via a non-invasive intranasal delivery i  ...[more]

Similar Datasets

| S-EPMC7610836 | biostudies-literature
| S-EPMC4072629 | biostudies-literature
2014-10-04 | E-GEOD-56780 | biostudies-arrayexpress
| S-EPMC3364340 | biostudies-literature
2014-10-04 | GSE56780 | GEO
| S-EPMC9633670 | biostudies-literature
| S-EPMC8093094 | biostudies-literature
| S-EPMC3437019 | biostudies-literature
| S-EPMC5379860 | biostudies-literature
| S-EPMC6978308 | biostudies-literature